Precisely Driving PROTAC Development: Human BCL6/CRBN Molecular Glue Binding Detection Kit
In the field of targeted protein degradation, particularly in the development of molecular glue drugs targeting the critical transcription factor BCL6, rapidly and accurately quantifying the efficiency of ternary complex formation induced by candidate compounds is a key step to accelerate lead compound discovery and optimization.
- Recent Advances
- Product Information
In the field of targeted protein degradation, particularly in the development of molecular glue drugs targeting the critical transcription factor BCL6, the ability to rapidly and accurately quantify the efficiency of candidate compound-induced ternary complex formation is a pivotal step in accelerating lead compound discovery and optimization.
To address this, we introduce the Human BCL6/CRBN PROTAC Binding Kit. This kit leverages advanced homogeneous time-resolved fluorescence (TR-FRET) technology, specifically designed for the quantitative detection of molecular glue (e.g., ARV-393)-mediated induced interactions between the DDB1/CRBN E3 ubiquitin ligase complex and the BCL6 target protein. It serves as a powerful tool for high-throughput screening and mechanistic studies.
I. Core Principle: Directly "Visualizing" Protein Complex Assembly
This kit employs a homogeneous, wash-free detection format, directly reporting ternary complex formation through sensitive TR-FRET signals.
Intelligent Detection Design: The kit provides Eu-labeled donor antibodies and acceptor-labeled receptor antibodies, which specifically recognize different tags on the DDB1/CRBN complex and BCL6 protein, respectively.
Key to Signal Generation: When an effective molecular glue (e.g., ARV-393) is present in the sample, it acts as a "bridge," inducing close spatial proximity between DDB1/CRBN and BCL6, thereby bringing the corresponding donor and receptor antibodies into close proximity.
From Energy Transfer to Specific Signal: When the donor Eu is excited by a specific light source, its energy is efficiently transferred to the nearby acceptor via fluorescence resonance energy transfer (FRET), ultimately generating a long-lived specific fluorescence signal at 665 nm. The intensity of this signal is directly proportional to the amount of ARV-393-mediated ternary complex formed, enabling precise quantification.
II. Why Choose This Kit? Core Advantages at a Glance
| Advantage Dimension | Limitations of Traditional Methods | This Kit's Solution |
|---|---|---|
| Workflow | Multi-step, requires washing (e.g., ELISA, Pull-down), time-consuming, low throughput. | Truly homogeneous detection: "add-mix-incubate-read," no washing steps, ultra-simple operation, automation-friendly. |
| Detection Quality | Susceptible to interference from short-lived fluorescence in sample matrix, low signal-to-noise ratio. | Time-resolved detection, delayed measurement effectively subtracts background interference, delivering ultra-high signal-to-noise ratio and stable, reliable data. |
| Throughput & Cost | Challenging for large-scale compound screening. | Optimized for 384- or 1536-well plates, tailored for high-throughput screening (HTS), significantly saving precious samples and reagent consumables. |
| Information Dimension | Typically limited to endpoint binding data. | Enables real-time kinetic monitoring, in-depth assessment of compound-induced binding rate and strength. |
III. Broad Application Scenarios
High-throughput screening of BCL6-targeting molecular glues/PROTACs: Rapidly identify novel active molecules from large compound libraries that induce CRBN-BCL6 binding.
Structure-activity relationship (SAR) studies: Precisely quantify the impact of structural modifications on a compound's induced binding efficacy (potency), efficiently guiding medicinal chemistry optimization.
Mechanism validation: Verify a candidate compound's ability to mediate specific ternary complex formation, clarifying its mode of action.
Compound potency ranking: Provide quantitative binding activity data for different candidate molecules, enabling prioritization and downstream development decisions.
IV. Summary
The Human BCL6/CRBN PROTAC Binding Kit transforms the complex detection of induced protein-protein interactions into a simple, rapid, and high-quality homogeneous assay workflow. It is the ideal choice for tackling the BCL6 target and accelerating the discovery of next-generation protein degraders.
About This Product
The Human BCL6/CRBN PROTAC Binding Kit (Product No.: UA086021) is developed and manufactured by UA-Bio. UA-Bio is dedicated to providing high-performance, reliable innovative detection solutions for cutting-edge life science exploration and drug development. The launch of this kit demonstrates our technical expertise in continuously delivering professional tools in advanced fields such as targeted protein degradation, empowering global academic and industrial users to enhance research efficiency.
Contact UA-Bio for detailed technical information and ordering instructions.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Business license (three certificates in one) 